ViaCyte stem cell implant shows first signs of insulin production in diabetes
Endpoints News - 25-Jun-2021Stem cell therapy triggers insulin production in a type 1 diabetes patient
Previously the Live Forever Club — same community, now with a sharper mission for life extension
Professor of medicine at Vrije Universiteit Brussel and diabetologist at UZ Brussel, specialising in type 1 diabetes and beta cell replacement
Bart Keymeulen is a full professor in the Faculty of Medicine and Pharmacy at Vrije Universiteit Brussel (VUB) and a diabetologist at UZ Brussel, where he leads integrated, multidisciplinary care for all forms of diabetes with a particular focus on type 1 diabetes. He chairs the VUB research cluster on Diabetes, Transplantation and Pathology and is honorary president of the Belgian Diabetes League.
His research aims to bring new therapies to people at every stage of type 1 diabetes, from prevention before diagnosis to treatment later in the disease. This includes immunotherapy to suppress the autoimmune attack on insulin-producing cells and the transplantation of beta cells, or stem cell-derived cells that mature into beta cells. He has been a principal investigator in clinical trials of stem cell-derived islet replacement therapy, and in 2022 he received the Hilde Bruers Prize for scientific research in medicine.
Visit website: https://www.uzbrussel.be/fr/web/diabeteskliniek/diabetologues/-/asset_publisher/yR1bwnadaSIc/content/prof-dr-bart-keymeulen
See alsoDetails last updated 16-Nov-2026
Stem cell therapy triggers insulin production in a type 1 diabetes patient